Omniome is developing a breakthrough DNA sequencing platform that delivers highly accurate and fast results at low cost with the potential to advance cancer diagnostics, drive high fidelity single-cell applications and broadly support clinical sequencing. Our scar-free, Sequencing By Binding™ (SBB™) technology provides enhanced precision of nucleotide and DNA matching by leveraging the natural matching ability of the polymerase, decreasing runtimes and increasing the number of samples per run.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 07/31/18 | $60,000,000 | Series B |
Altitude Life Science Ventures ARCH Venture Partners Biomatics Capital Decheng Capital  Domain Associates Hillhouse Capital Group LAM Research Nan Fung | undisclosed |
| 01/09/20 | $60,000,000 | Series C |
Altitude Life Sciences Ventures ARCH Venture Partners Biomatics Capital Decheng Capital Domain Associates Nan Fung | undisclosed |
